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Background
The next generation NNRTI etravirine (ETR, TMC125) has
shown strong and durable efficacy in the DUET trials in
combination with a background regimen of darunavir/r,
NRTIs and optional enfuvirtide. The expanded access pro-
gramme included a wider range of background regimens
(BR).
Methods
The TMC125-C214 trial (etravirine expanded access pro-
gramme) included patients with triple class experience
(NRTI, PI, NNRTI) and who were unable to use currently
approved NNRTIs owing to either intolerance or drug
resistance. Patients were recruited from ten countries in
Europe and received etravirine 200 mg BID with a range
of background antiretrovirals.
Summary of results
By 31st May 2008, there were 877 European patients with
data available: 21% were female, 87% were Caucasian,
with a mean age of 46 years. The baseline mean CD4
count was 278 cells/uL (range 0–1647) with baseline
mean HIV-RNA 5248 copies/mL (range 40 – 3,263,277).
667/882 (76%) patients used at least one PI, of which 606
(91%) used DRV/r. 251/882 (28.5%) patients did not use
NRTIs in the background regimen. Of the 631 patients
using NRTIs, the most common were tenofovir (69%),
3TC or FTC (91%), ZDV (20%) and ABC (18%). Other
antiretrovirals used included raltegravir (54%) and mara-
viroc (14%). The percentage of patients with HIV-RNA
<50 copies/mL was 13% at week 4, 48% at week 12 and
67% at week 24 (observed data analysis). CD4 counts rose
by mean 75 cells/uL at week 12 and by 89 cells/uL at week
24. There were 131 serious adverse events (SAE's)
recorded, of which 117 (89%) were judged to be not
related to etravirine or doubtful causality. There were 14
SAE's judged to be at least possibly related to etravirine. Of
these, there were five (0.6%) cases of rash (ETR perma-
nently stopped in 4/5 cases), one elevation of ALT levels
(0.1%) (ETR dose not changed) and one case of choles-
tatic acute hepatitis (0.1%) (ETR dose not changed).
Conclusion
The use of etravirine in the expanded access programme
included a wide range of antiretrovirals in the background
regimen, with a high percentage of patients showing HIV-
RNA suppression below 50 copies/mL by weeks 12–24.
Serious adverse events were mainly unrelated to ETR.
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